Skip to main content

Resistance to antiplatelet drugs: current status and future research.

Publication ,  Journal Article
Tantry, US; Bliden, KP; Gurbel, PA
Published in: Expert Opin Pharmacother
October 2005

Platelet reactivity and activation are important factors during the development of atherothrombotic processes and subsequent ischaemic complications. Pharmacological agents that suppress platelet function are proved to be the most efficient in the prevention and treatment of thrombotic complications. As the activation of platelets during thrombus generation involves many complex and redundant pathways, simultaneous use of different antiplatelet drugs that are directed against different targets have been effective in reducing adverse clinical events. The main antiplatelet drugs are aspirin (which inhibits thromboxane synthesis), thienopyridines (which block P2Y12 receptors) and glycoprotein IIb/IIIa antagonists (which block glycoprotein IIb/IIIa receptors). In recent years, resistance or nonresponsiveness to antiplatelet therapy has been reported and, more importantly, are linked to the occurrence of adverse cardiovascular events. New treatment strategies to overcome nonresponsiveness are being sought. A focus on the development of simple, reproducible and user friendly point-of-care methods to determine aspirin/clopidogrel responsiveness should be undertaken to assist clinicians in tailoring antiplatelet therapy to the individual patient.

Duke Scholars

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

October 2005

Volume

6

Issue

12

Start / End Page

2027 / 2045

Location

England

Related Subject Headings

  • Thrombosis
  • Point-of-Care Systems
  • Platelet Aggregation Inhibitors
  • Platelet Activation
  • Pharmacology & Pharmacy
  • Humans
  • Drug Resistance, Neoplasm
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tantry, U. S., Bliden, K. P., & Gurbel, P. A. (2005). Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother, 6(12), 2027–2045. https://doi.org/10.1517/14656566.6.12.2027
Tantry, Udaya S., Kevin P. Bliden, and Paul A. Gurbel. “Resistance to antiplatelet drugs: current status and future research.Expert Opin Pharmacother 6, no. 12 (October 2005): 2027–45. https://doi.org/10.1517/14656566.6.12.2027.
Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother. 2005 Oct;6(12):2027–45.
Tantry, Udaya S., et al. “Resistance to antiplatelet drugs: current status and future research.Expert Opin Pharmacother, vol. 6, no. 12, Oct. 2005, pp. 2027–45. Pubmed, doi:10.1517/14656566.6.12.2027.
Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother. 2005 Oct;6(12):2027–2045.

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

October 2005

Volume

6

Issue

12

Start / End Page

2027 / 2045

Location

England

Related Subject Headings

  • Thrombosis
  • Point-of-Care Systems
  • Platelet Aggregation Inhibitors
  • Platelet Activation
  • Pharmacology & Pharmacy
  • Humans
  • Drug Resistance, Neoplasm
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences